ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness

Zacks Investment Research News Agency

4 hours ago•Zacks Investment Research

Stocks Medium Importance Neutral

ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness

ADMA Biologics matches earnings estimates, misses on revenues and maintains its 2026 outlook as strong Asceniv growth offsets continued pressure on Bivigam.

Related Symbols 1

A ADMA ADMA

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Comments

No comments yet

Be the first person to comment on this news item.

Category Stocks

Source Zacks Investment Research

Published 4 hours ago

Likes 0

Comments 0

Shares 0

News ID #2,128

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.

ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness

Comments

User Menu